Global Payments Inc vs Revvity Inc — how do they compare? Global Payments Inc trades at $82.2 (market cap $21.46B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays the higher dividend (1.23%). Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Revvity Inc for 12 Days on average.
| GPN | RVTY | |
|---|---|---|
Market Cap | $21.46B | $16.98B |
Volume | 1,482,600 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $94.83 | $157.36 |
52-Week Low | $62.47 | $82.26 |
Typical Hold Time | 50 Days | 12 Days |
Enterprise Value | $39.60B | $19.30B |
Dividend Yield | 1.23% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.77, up 2.08% with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net income margin and ROE. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains strongly bullish with a $102.75 price target.
GPN presents a mixed outlook with strong analyst support and strategic initiatives offset by profitability concerns and rising debt levels. The stock offers 24% upside to consensus targets but faces execution risks in integrating acquisitions and maintaining margin expansion amid competitive pressures in the payments technology sector.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →